Healthcare Industry News: anastomosis
News Release - February 8, 2010
Synovis Life Technologies Receives FDA Marketing Clearance for Flow Coupler(R)Microsurgical Device Assesses Blood Flow After Connecting Small Blood Vessels
ST. PAUL, Minn.--(HSMN NewsFeed)--Synovis Life Technologies, Inc. (Nasdaq: SYNO ), has received Food and Drug Administration 510(k) marketing clearance for its Flow Coupler®, an innovative extension of the company’s well-established Microvascular Anastomotic Coupler used in several surgical procedures to connect small blood vessels more quickly and with equal or greater reliability than hand suturing. The Flow Coupler incorporates Doppler technology to immediately measure blood flow after connecting the small blood vessels. Synovis will begin a limited launch of the Flow Coupler in the United States during its second fiscal quarter with a full release expected during the company’s fiscal third quarter.
“We are extremely pleased to receive FDA marketing clearance for the Flow Coupler – a milestone achievement for Synovis,” said Richard W. Kramp, Synovis Life Technologies president and chief executive officer. “The Flow Coupler’s added feature of providing real time blood flow information makes this an extraordinary product which will assist surgeons in ascertaining that critical blood supply to transplanted soft tissue has been achieved. We believe the Flow Coupler has more than twice the potential market opportunity of the Coupler, and reinforces our microsurgical group’s position as ‘the microsurgeon’s most trusted resource.’ Our specialized microsurgical sales force is eager to offer surgeons the Flow Coupler.”
The Flow Coupler incorporates a 20MHz Doppler sensor to measure blood flow at the site where the vessel is joined (the anastomosis). The Doppler sensor provides surgeons reliable, real time information about blood flow through the anastomosis, enabling immediate intervention in the event of a blockage at the site. Synovis previously received a U.S. patent on this advanced technology.
Synovis’ original Coupler is widely used in microvascular surgery, including breast reconstruction in cancer patients, as well as in several applications in head, neck and hand reconstruction. The device provides a patency rate exceeding that of hand suturing while connecting vessels in approximately one-fifth of the time required by hand suturing, resulting in shorter aschemic time for the transplanted tissue, significant time savings in the operating room and cost savings.
About Synovis Life Technologies
Synovis Life Technologies, Inc., based in St. Paul, Minn., develops, manufactures and markets mechanical and biological products used by several surgical specialties for the repair of soft tissue damaged or destroyed by disease or injury. The company’s products are designed to reduce risks and/or facilitate critical surgeries, improve patient outcomes and reduce healthcare costs. For additional information on Synovis Life Technologies and its products, visit the company’s Web site at www.synovislife.com.
Forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements can be identified by words such as “should”, “could”, “may”, “will”, “expect”, “believe”, “anticipate”, “estimate”, “continue”, or other similar expressions. Certain important factors that could cause results to differ materially from those anticipated by the forward-looking statements made herein include the timing of product introductions, the ability of our expanded direct sales force to grow revenues, outcomes of clinical and marketing studies as well as regulatory submissions, the number of certain surgical procedures performed, the ability to identify, acquire and successfully integrate suitable acquisition candidates (such as the recently acquired Orthopedic and Woundcare products), any operational or financial impact of the current global economic downturn, as well as the other factors found in the company’s reports to the Securities and Exchange Commission, including on the company’s Annual Report on Form 10-K for the year ended October 31, 2009.
Source: Synovis Life Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.